- List
- By Topic
- On Map
- Search Details

Recruiting, Not yet recruiting, Available Studies | "Triplets"
Need help? See RSS Feeds
Choose a feed type:

Recruiting, Not yet recruiting, Available Studies | "Triplets" (380 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03244358 | Recruiting | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
30 | Female | 18 Years to 70 Years (Adult, Senior) | NCT03244358 | SYSUCC-010 | March 1, 2017 | July 1, 2018 | July 1, 2018 | August 9, 2017 | January 17, 2018 |
|
||
2 | NCT03154749 | Recruiting | TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
74 | Female | 18 Years to 70 Years (Adult, Senior) | NCT03154749 | 20170512 | September 1, 2016 | September 1, 2018 | September 1, 2019 | May 16, 2017 | May 16, 2017 |
|
||
3 | NCT01216111 | Available | Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer |
|
|
Expanded Access |
|
Other | Female | 18 Years to 65 Years (Adult) | NCT01216111 | Fudan TNBC Adjuvant CT | October 7, 2010 | October 7, 2010 | ||||||||||
4 | NCT02977468 | Recruiting | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
15 | Female | 21 Years to 80 Years (Adult, Senior) | NCT02977468 | AAAQ7863 | Pembro/IORT | October 25, 2017 | December 2019 | December 2020 | November 30, 2016 | January 5, 2018 |
|
|
5 | NCT02247037 | Recruiting | Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer |
|
|
Observational |
|
Other / Industry |
|
|
140 | All | 18 Years to 90 Years (Adult, Senior) | NCT02247037 | GCO 14-0686 | July 2014 | June 2019 | June 2019 | September 23, 2014 | July 21, 2017 |
|
|||
6 | NCT03243838 | Not yet recruiting | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
40 | Female | 18 Years to 70 Years (Adult, Senior) | NCT03243838 | 20170328 | LANCET | April 2, 2018 | December 30, 2019 | December 30, 2019 | August 9, 2017 | February 6, 2018 |
|
|
7 | NCT03358017 | Not yet recruiting | Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
154 | Female | 18 Years and older (Adult, Senior) | NCT03358017 | IRFMN-BRC-7103 2016-005112-17 |
YAPPETIZER | December 15, 2017 | July 25, 2020 | July 25, 2020 | November 30, 2017 | November 30, 2017 |
|
|
8 | NCT02993094 | Recruiting | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
53 | Female | 18 Years and older (Adult, Senior) | NCT02993094 | AGMT_MBC-10 (X16087) 2016-001421-13 |
November 2016 | September 2019 | September 2019 | December 15, 2016 | November 24, 2017 |
|
||
9 | NCT03077776 | Recruiting | Tracking Triple-negative Breast Cancer Evolution Through Therapy |
|
|
Interventional | Not Applicable |
|
Other |
|
|
250 | All | 18 Years and older (Adult, Senior) | NCT03077776 | UC0105/1614 ID RCB: 2016-A01177-44 |
TRACERX-TNBC | April 14, 2017 | January 2025 | July 2025 | March 13, 2017 | November 1, 2017 |
|
|
10 | NCT03499899 | Not yet recruiting New |
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
126 | All | 18 Years and older (Adult, Senior) | NCT03499899 | CLAG525B2101 | June 20, 2018 | September 30, 2019 | October 12, 2020 | April 17, 2018 | April 17, 2018 | |||
11 | NCT02266420 | Recruiting | Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm |
|
|
Interventional | Not Applicable |
|
Other |
|
|
200 | Female | 18 Years and older (Adult, Senior) | NCT02266420 | 14 SEIN 09 | COCABIO000 | October 23, 2014 | October 2021 | October 2022 | October 17, 2014 | October 25, 2017 |
|
|
12 | NCT02161679 | Not yet recruiting | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
80 | All | 18 Years to 90 Years (Adult, Senior) | NCT02161679 | IMMU-132-02 | August 2016 | August 2018 | June 12, 2014 | October 12, 2015 | ||||
13 | NCT03175666 | Not yet recruiting | NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
79 | All | 18 Years and older (Adult, Senior) | NCT03175666 | QUILT-3.049 | December 2017 | January 2019 | March 2019 | June 5, 2017 | October 30, 2017 | |||
14 | NCT03457779 | Recruiting | Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
16 | Female | 18 Years and older (Adult, Senior) | NCT03457779 | 017-396 | February 8, 2018 | August 8, 2019 | August 8, 2020 | March 8, 2018 | March 8, 2018 |
|
||
15 | NCT03167619 | Not yet recruiting | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
60 | Female | 21 Years and older (Adult, Senior) | NCT03167619 | Pro00080769 | DORA | May 2018 | October 2019 | April 2020 | May 30, 2017 | January 4, 2018 | ||
16 | NCT03387085 | Not yet recruiting | QUILT-3.067 NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
79 | All | 18 Years and older (Adult, Senior) | NCT03387085 | QUILT-3.067 | January 2018 | January 2019 | January 2020 | December 29, 2017 | January 8, 2018 |
|
||
17 | NCT03444025 | Not yet recruiting | Neoadjuvant Goserelin for Triple Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
180 | Female | 18 Years to 60 Years (Adult) | NCT03444025 | B2017-11 | NeoGONT | March 2018 | March 2021 | March 2023 | February 23, 2018 | February 23, 2018 | ||
18 | NCT03251313 | Not yet recruiting | PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients |
|
|
Interventional | Phase 1 |
|
Other |
|
|
33 | Female | 18 Years to 70 Years (Adult, Senior) | NCT03251313 | Fudan-P1-201701 | November 2017 | December 2019 | December 2020 | August 16, 2017 | October 27, 2017 | |||
19 | NCT03473691 | Not yet recruiting New |
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer |
|
|
Interventional | Early Phase 1 |
|
Other / Industry |
|
|
12 | All | 18 Years and older (Adult, Senior) | NCT03473691 | TBDBreast50 | Breast50 | March 31, 2018 | March 31, 2021 | March 31, 2023 | March 22, 2018 | March 22, 2018 | ||
20 | NCT03193853 | Recruiting | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
20 | Female | 18 Years and older (Adult, Senior) | NCT03193853 | 017- 113 PIKTOR Baylor 017-113 |
July 18, 2017 | June 9, 2021 | June 9, 2022 | June 21, 2017 | February 12, 2018 |
|
||
21 | NCT02768701 | Recruiting | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
36 | All | 18 Years and older (Adult, Senior) | NCT02768701 | LCCC 1525 | October 2016 | December 2018 | December 2022 | May 11, 2016 | October 18, 2017 |
|
||
22 | NCT02984683 | Recruiting | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
62 | All | 18 Years and older (Adult, Senior) | NCT02984683 | ACT14884 2016‐001962‐27 U1111-1182-7044 |
March 14, 2017 | December 20, 2019 | December 20, 2019 | December 7, 2016 | April 12, 2018 |
|
||
23 | NCT03424005 | Recruiting | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC) |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
260 | All | 18 Years and older (Adult, Senior) | NCT03424005 | CO40115 2017-002038-21 |
Morpheus-TNBC | March 15, 2018 | August 1, 2021 | August 1, 2021 | February 6, 2018 | March 2, 2018 |
|
|
24 | NCT03281954 | Recruiting | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo |
|
|
Interventional | Phase 3 |
|
Other / Industry |
|
|
1520 | All | 18 Years and older (Adult, Senior) | NCT03281954 | NSABP B-59/GBG 96-GeparDouze 2017-002771-25 MO39875 |
December 19, 2017 | December 31, 2023 | June 30, 2024 | September 13, 2017 | March 30, 2018 |
|
||
25 | NCT03498716 | Not yet recruiting New |
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
|
|
Interventional | Phase 3 |
|
Industry / Other |
|
|
2300 | All | 18 Years and older (Adult, Senior) | NCT03498716 | WO39391 2016-003695-47 BIG 16-05 AFT-27 |
IMpassion030 | April 25, 2018 | January 15, 2022 | December 29, 2024 | April 17, 2018 | April 17, 2018 |
|
|
26 | NCT03371017 | Recruiting | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
350 | All | 18 Years and older (Adult, Senior) | NCT03371017 | MO39193 2016-005119-42 |
IMpassion132 | January 31, 2018 | July 31, 2019 | January 31, 2021 | December 13, 2017 | December 27, 2017 |
|
|
27 | NCT03168880 | Recruiting | A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer |
|
|
Interventional | Phase 3 |
|
Other |
|
|
720 | Female | 18 Years to 70 Years (Adult, Senior) | NCT03168880 | CTRI/2012/07/002802 | TNBC | April 2010 | November 30, 2019 | November 30, 2024 | May 30, 2017 | May 30, 2017 |
|
|
28 | NCT03358004 | Recruiting | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment |
|
|
Interventional | Phase 2 |
|
Other |
|
|
180 | Female | 18 Years and older (Adult, Senior) | NCT03358004 | IRFMN-BRC-6992 | VICTOR3 | October 30, 2017 | September 15, 2019 | September 15, 2020 | November 30, 2017 | November 30, 2017 |
|
|
29 | NCT03197935 | Recruiting | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
204 | All | 18 Years and older (Adult, Senior) | NCT03197935 | WO39392 2016-004734-22 |
IMpassion031 | July 25, 2017 | March 19, 2019 | September 26, 2021 | June 23, 2017 | April 17, 2018 |
|
|
30 | NCT02413320 | Recruiting | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
100 | Female | 18 Years to 70 Years (Adult, Senior) | NCT02413320 | 2015-IIT-Neoadjuvant-BRST-TNBC | NeoSTOP | July 2015 | July 2018 | December 2018 | April 9, 2015 | October 30, 2017 |
|
|
31 | NCT03125902 | Recruiting | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
540 | All | 18 Years and older (Adult, Senior) | NCT03125902 | MO39196 2016-004024-29 |
IMpassion131 | August 25, 2017 | February 28, 2019 | June 30, 2021 | April 24, 2017 | April 10, 2018 |
|
|
32 | NCT02124902 | Recruiting | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity |
|
|
Interventional | Phase 2 |
|
Other |
|
|
85 | Female | 18 Years and older (Adult, Senior) | NCT02124902 | 201404107 | July 7, 2014 | September 30, 2018 | September 30, 2018 | April 28, 2014 | April 12, 2018 |
|
||
33 | NCT03036488 | Recruiting | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
855 | All | 18 Years and older (Adult, Senior) | NCT03036488 | 3475-522 2016-004740-11 173567 |
March 7, 2017 | November 1, 2018 | March 14, 2025 | January 30, 2017 | April 20, 2018 |
|
||
34 | NCT03121352 | Recruiting | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT03121352 | CASE6115 | May 19, 2017 | March 2019 | March 2019 | April 20, 2017 | June 8, 2017 |
|
||
35 | NCT03002103 | Recruiting | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
420 | Female | 18 Years and older (Adult, Senior) | NCT03002103 | CT4005 | November 2016 | December 2021 | December 2022 | December 23, 2016 | March 23, 2018 |
|
||
36 | NCT02926196 | Recruiting | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab |
|
|
Interventional | Phase 3 |
|
Other |
|
|
335 | All | 18 Years and older (Adult, Senior) | NCT02926196 | A-BRAVE-Trial 2016-000189-45 |
A-Brave | June 2016 | June 2021 | June 2023 | October 6, 2016 | June 20, 2017 |
|
|
37 | NCT03254654 | Recruiting | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
66 | Female | 18 Years to 70 Years (Adult, Senior) | NCT03254654 | Fudan BR2017-23 | August 16, 2017 | August 2019 | August 2020 | August 18, 2017 | January 23, 2018 |
|
||
38 | NCT03145961 | Recruiting | A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients |
|
|
Interventional | Phase 2 |
|
Other |
|
|
200 | All | 16 Years and older (Child, Adult, Senior) | NCT03145961 | ICR-CTSU/2016/10058 2017-000508-92 |
c-TRAK-TN | December 21, 2017 | June 1, 2021 | December 1, 2022 | May 9, 2017 | January 29, 2018 |
|
|
39 | NCT03055312 | Recruiting | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer |
|
|
Interventional | Phase 3 |
|
Other |
|
|
262 | Female | 18 Years to 70 Years (Adult, Senior) | NCT03055312 | SYSUCC-007 | SYSUCC-007 | December 2016 | December 2020 | December 2020 | February 16, 2017 | September 11, 2017 |
|
|
40 | NCT02834403 | Recruiting | L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
48 | Female | 18 Years and older (Adult, Senior) | NCT02834403 | Pro00011685 | July 2016 | August 2019 | August 2019 | July 15, 2016 | March 29, 2018 |
|
||
41 | NCT02819518 | Recruiting | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
858 | All | 18 Years and older (Adult, Senior) | NCT02819518 | 3475-355 2016-001432-35 163422 MK-3475-355 |
July 27, 2016 | December 30, 2019 | December 30, 2019 | June 30, 2016 | March 22, 2018 |
|
||
42 | NCT03348098 | Recruiting | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 75 Years (Adult, Senior) | NCT03348098 | AHEAD TB001 | September 6, 2017 | July 6, 2018 | December 6, 2018 | November 20, 2017 | November 28, 2017 |
|
||
43 | NCT02422498 | Recruiting | Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy |
|
|
Interventional | Phase 2 |
|
Other |
|
|
54 | Female | 18 Years and older (Adult, Senior) | NCT02422498 | 15-032 | April 2015 | April 2019 | April 2019 | April 21, 2015 | January 12, 2018 |
|
||
44 | NCT02926690 | Recruiting | Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
70 | All | 18 Years and older (Adult, Senior) | NCT02926690 | OTS1070103 | May 29, 2017 | January 2020 | April 2020 | October 6, 2016 | July 2, 2017 |
|
||
45 | NCT03362060 | Recruiting | PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
20 | Female | 18 Years and older (Adult, Senior) | NCT03362060 | 17-328 | December 12, 2017 | December 31, 2020 | December 31, 2024 | December 5, 2017 | April 9, 2018 |
|
||
46 | NCT01216124 | Available | Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients |
|
|
Expanded Access |
|
Other | Female | 18 Years to 65 Years (Adult) | NCT01216124 | Fudan TNBC Neo CT | October 7, 2010 | October 7, 2010 | ||||||||||
47 | NCT03243331 | Recruiting | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer |
|
|
Interventional | Phase 1 |
|
Other |
|
|
18 | All | 18 Years and older (Adult, Senior) | NCT03243331 | IUSCC-0613 | January 19, 2018 | August 1, 2019 | January 1, 2020 | August 9, 2017 | February 12, 2018 |
|
||
48 | NCT03186937 | Recruiting | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
25 | Female | 18 Years and older (Adult, Senior) | NCT03186937 | UW16083 2016-1532 P30CA014520 NCI-2017-01047 |
August 10, 2017 | June 30, 2018 | June 30, 2019 | June 14, 2017 | September 6, 2017 |
|
||
49 | NCT02348320 | Recruiting | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy |
|
|
Interventional | Phase 1 |
|
Other |
|
|
30 | Female | 18 Years and older (Adult, Senior) | NCT02348320 | 201505074 | June 17, 2015 | June 30, 2019 | June 30, 2019 | January 28, 2015 | March 29, 2018 |
|
||
50 | NCT02802423 | Not yet recruiting | A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Docetaxel Monotherapy in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC). |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
44 | Female | 20 Years to 70 Years (Adult, Senior) | NCT02802423 | BLI-1401-2-01 | August 2016 | June 2018 | September 2018 | June 16, 2016 | June 16, 2016 |
† Study has passed its completion date and status has not been verified in more than two years.